40 MARCUS DRIVE, MELVILLE, NY
Announces Closing of $5.0 Million Public Offering
Investor Presentation
Announces $1.085 Million Registered Direct Offering Priced Above Market
Shareholder votes
Patient Numbers Up: From 15 to 36 subjects since last update, nearing Phase 2 goal of 99.
FY 2025
Q3
Q2
Q1
FY 2024
Amended Annual Report
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Direct Registration System
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
PRE 14A
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership